DRG Epidemiology's coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of CML for each country as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the developed world.

DRG Epidemiology's CML forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with CML per year?
  • How will improvements in survival change the number of people diagnosed with CML per year?
  • Of all people diagnosed with CML, how many in each country across the world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CML over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but they may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following CML patient populations:

  • CML diagnosed incident cases.
  • CML diagnosed incident cases by phase distribution.
  • CML diagnosed prevalent cases.
  • CML progression events.
  • CML drug-treated subpopulation(s).

Table of contents

  • Chronic Myeloid Leukemia - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Chronic Myeloid Leukemia per 100,000 People of All Ages in 2020 and 2040
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Chronic Myeloid Leukemia Over the Next 20 Years
          • Prevalence of Chronic Myeloid Leukemia per 100,000 People of All Ages in 2020 and 2040
          • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Chronic Myeloid Leukemia Over the Next 20 Years
      • Epidemiology Data
      • Methods
        • Diagnosed Incident Cases
        • Phase at Diagnosis
        • Diagnosed Prevalent Cases
        • Drug-Treated Populations
        • Progression Events
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Chronic Myeloid Leukemia
          • Studies Excluded from the Analysis of Chronic Myeloid Leukemia
        • Risk/Protective Factors
          • Risk/Protective Factors for Chronic Myeloid Leukemia
        • Bibliography
        • Glossary

    Author(s): Pramilesh Tekchand Suryawanshi; Nishant Kumar, M.P.H.

    Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Before joining DRG, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.

    Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.